喻秋華研究員

喻秋華 研究員
分子與基因醫學研究所
連絡電話:886-37-246166 ext. 35338
傳真電話:886-37-586459
E-mail:chyuh@nhri.edu.tw

 

 

 

 

學歷

Ph.D., Microbiology and Immunology, National Yang-Ming Medical College, Taipei, Taiwan (1992)
B.S., Biology, Fu-Jen Catholic University, Taipei, Taiwan (1987)

經歷

2015/10 – present

Joint Professor, Department of the Biological Science & Technology, National Chiao Tung University, HsincChu, Taiwan

2015/10 – present

Adjunct Professor, Institute of Bioinformatics and Structural Biology, National Tsing Hua University, HsincChu, Taiwan

2015/10 – present

Investigator, Division of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan

2015/08 – 2017/12

Joint Professor, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

2011/08 – 2015/09

Joint Associate Professor, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

2007/08 – 2015/09

Joint Associate Professor, Department of the Biological Science & Technology, National Chiao Tung University, HsincChu, Taiwan

2006/08 – 2015/09

Adjunct Associate Professor, Institute of Bioinformatics and Structural Biology, National Tsing Hua University, HsincChu, Taiwan

2005/01 – 2015/09

Associate Investigator, Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan

2002/08 – 2004/12

Member of the Professional Staff, Biology Division, California Institute of Technology, Pasadena, California, USA

2001/08 – 2002/07

Director, Transcription Factor Center, Beckman Institute,, California Institute of Technology, Pasadena, California, USA

1996/08 – 2001/07

Research Associate, Division of Medical Research, Stowers Institute of Medical Research, Missoli, USA

1995/08 – 2001/07

Senior Research Fellow, Biology Division, California Institute of Technology, Pasadena, California, USA

1992/08 – 1995/07

Research Fellow, Biology Division, California Institute of Technology, Pasadena, California, USA

1989/08 – 1992/07

Teaching Assistant, Institute of Microbiology and Immunology, National Yang-Ming Medical College, Taipei, Taiwan

研究興趣

Dr. Yuh is interested in gene regulation during development and carcinogenesis. Over the course of Dr. Yuh’s career in life science, she identified second enhancer (enhancer II) of hepatitis B virus and discovered the action mechanism of enhancer II and the core promoter of the HBV and received her Ph.D. from Institute of Microbiology and Immunology at National Yang-Ming Medical College, Taiwan in 1992. She published five international papers and one book chapter during five years. Dr. Yuh gained tremendous experience on the systematic approached of embryonic development and Gene Regulatory Networks (GRNs) in California Institute of Technology (Caltech) under the supervision of Dr. Eric Davidson. She decoded the regulatory circuits of endoderm specific gene in sea urchin, Endo16 and published the paper in Science on 1998, using computational algorisms to explain the transcription regulation. Dr. Yuh also participated on establishment of the Endomesoderm Gene Regulatory Network in sea urchin. Seventeen scientific high impact papers and three book chapters were published before she joined NHRI.

Dr. Yuh was recruited as an Associate Investigator by the DMGM of NHRI at December 31 of 2004, and started using zebrafish as model organism to decode the embryonic gene regulatory networks. Using a web-enabled GRN modeling tool (BioTapestry) to build an integrated model of the Endomesoderm Gene Regulatory Network in zebrafish, functional dissecting the important subcircuits in the endoderm networks by systematically approaches, she identified several interesting functional motifs that are important building blocks in zebrafish developmental GRNs, and published six papers on international well known journals such as Developmental Biology, BMC Developmental Biology and Birth Defects Research Part C.

For the translational research, Dr. Yuh had found the genes and pathways in development were dysregulated in cancer. She initiated the systematic analysis of hepatocellular carcinoma (HCC) in mouse model, and established transgenic zebrafish model. Dr. Yuh has identified five critical oncogenes from mouse model, verified using human HCC specimens, and confirmed in transgenic zebrafish. Dr. Yuh is currently interested in the mechanism of ribose-5-phosphate isomerase A (RPIA) in human hepatocellular carcinoma (HCC) and colorectal cancer. She is also studying the overexpression of alpha-mannosidase 1A1, 1A2, and 1B1 as well as down-regulation of alpha-mannosidase 1C1 during hepatocarcinogenesis.

For application, Dr. Yuh’s further develops the drug screening platform to identified novel small molecules which are effective in treatment HCC and lower toxicity compared to Sorafenib. Dr. Yuh’s lab have established high throughput anti-angiogenesis screening using fli1:EGFP transgenic fish. Dr. Yuh also have established xenotransplantation assay, for the anti-proliferation ability and anti-migration ability. We have tested the anti-HCC effects of those candidate drugs using adult transgenic fish with HCC, orbital injection or oral feeding of drugs for their anti-HCC effects. Using liver florescence zebrafish embryos, Dr. Yuh can examine their hepatoxicity, and also examine their embryonic toxicity. Therefore, the data proved that the zebrafish platform was an excellent model for identification of new anti-cancer drugs.

In cancer research, the unanswered questions and grand challenges are complexity of genomes and drug resistance, and long-term drug treatment to control cancer is a major challenge. After a period of targeting therapy, in about 2 to 3 months, eventually drug resistance occurs. From our previous patient-derived xenograft model of colorectal cancer zebrafish personalized drug screening, Dr. Yuh found that the drug inhibition lost along with tumor cell’s passage increases. This result prompted us to investigate the genomic evolution of drug resistance, and test new clinical available target therapies for the resistant tumors.

The toxicity of anti-cancer drugs is the biggest problem for cancer treatment; it may cause lots of side effect. Using liver specific fluorescence transgenic fish embryos, Dr. Yuh found 420S1 and Sorafenib will reduce liver RFP intensity and shrank liver size, however, the fish treated with 419S1 resembled the DMSO control. Therefore, the 419S1 may have less hepatotoxicity. With the integrated efforts and the advantage of zebrafish platform, Dr. Yuh can find more effective and safe drugs for anti-HCC.

In addition to her research, Dr. Yuh has been active in teaching and prompt Systems Biology in Taiwan. Dr. Yuh has been teaching Gene Regulatory Network and Systems Biology in National Tsing-Hua University, National Chiao Tung University, and National China Medical College.

榮譽與獲獎

2018    Liver Disease Prevention Research Foundation Fellowship
2015    Liver Disease Prevention Research Foundation Fellowship
2014    Liver Disease Prevention Research Foundation Fellowship
2012    Liver Disease Prevention Research Foundation Fellowship
1995    Biology Divisional Fellowship, California Institute of Technology
1994    Gordon Ross Fellowship, California Institute of Technology
1993    Procter and Gamble Fellowship, California Institute of Technology
1991    First prize scholarship from Wang Ming-Ning Memorial Foundation, Taiwan
1984-1987    Ranked-First Scholarship Award, Fu-Jen Catholic University, Taiwan

專利

  1. EARLY BIOMARKER FOR HEPATOCELLULAR CARCINOMA (早期階段檢測肝癌及預測肝癌轉移之方法), Taiwan Patent Number: I440855, 2014/06/11~2031/07/26 (granted), Horng-Dar Wang, Chiou-Hwa Yuh, Yung-Chun Hsiao, Yu-Ting Chou
  2. Method for inducing cancer cell apoptosis or inhibiting the cancer cell migration , United States Patent Application number 13/195,143, 2014/5/3 (granted), Horng-Dar Wang, Chiou-Hwa Yuh, Yu-Ting Chou, Shih-Ci Chou
  3. EARLY BIOMARKER FOR HEPATOCELLULAR CARCINOMA (Split application), United States Patent Application number 14/099,685, 2013/12/6(pending) , Horng-Dar Wang, Chiou-Hwa Yuh, Hsiao-Chen Tu, Yu-Ting Chou
  4. RPIA promote cancer cell apoptosis or inhibit migration (核酮糖五磷酸異構酶A促進癌細胞凋亡或抑制癌細胞轉移的方法), Taiwan Patent Number: I418361, 2013/12/11~2031/04/07 (granted), Horng-Dar Wang, Chiou-Hwa Yuh, Yu-Ting Chou, Shih-Ci Chou
  5. EARLY BIOMARKER FOR HEPATOCELLULAR CARCINOMA, United States Patent Application number 13/220,055, 2013/9/9 (granted), Horng-Dar Wang, Chiou-Hwa Yuh, Yung-Chun Hsiao, Yu-Ting Chou

學術著作

  1. Wu SY , Yang WY, Cheng CC, Hsiao MC, Tsai SL, Lin HK, Lin KH, Yuh CH*, Low Molecular Weight Fucoidan Prevents Radiation-Induced Fibrosis and Secondary Tumors in A Zebrafish Model, Cancers, 2020 June 16. 1608
  2. Sie ZL, Li RY, Sampurna BP, Hsu PJ, Liu SC, Wang HD, Huang CL*Yuh CH*, WNK1 Kinase Stimulates Angiogenesis to Promote Tumor Growth and Metastasis, Cancers, 2020 Mar 2;12(3).
  3. Yang WY, Rao PS, Luo YC, Lin HK,  Huang SH, Yang JM*, Yuh CH*, Omics-based Investigation of Diet-induced Obesity Synergized with HBx, Src, and p53 Mutation Accelerating Hepatocarcinogenesis in Zebrafish Model, Cancers 2019 Nov., 11(12):1899
  4. Su ZL, Su CW, Huang YL, Yang WY, Sampurna BP, Ouchi T, Lee KL, Wu CS, Wang HD*, Yuh CH*, A novel AURKA mutant-induced early-onset severe hepatocarcinogenesis greater than wild-type via activating different pathways in zebrafish, Cancers (Basel). 2019 July 2;11(7). pii: E927
  5. Lin HS, Huang YL, Wang YS, Hsiao E, Hsu TA, Shiao HY, Jiaang WT, Sampurna BP, Lin KH, Wu MS, Lai GM, Yuh CH*, Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform. Cancers (Basel). 2019 May 28;11(6). pii: E739 
  6. Chou YT,  Chen LY, Tsai SL, Tu HC, Lu JW, Ciou SC, Wang HD*, Yuh CH*, Ribose-5-Phosphate Isomerase A (RPIA) Overexpression Promotes Liver Cancer Development in Transgenic Zebrafish via activation of ERK and β-catenin pathways, Carcinogenesis, 2019 May; 40(3): 461–473. 
  7. Liu SC, Hsu T, Chang YS, Chung AK, Jiang SS, OuYang CN, Yuh CH, Hsueh C, Liu YP. Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through YAP1-FAK/PXN signaling, Nature Communications, 2018 Nov., 9:5105
  8. Chou YT, Jiang JK, Yang MH, Lu JW, Lin HK, Wang HD*, Yuh CH*, Identification of a non-canonical function for ribose-5-phosphate isomerase A promotes colorectal cancer formation by stabilizing and activating β-catenin via a novel C-terminal domain, PLoS Biology, 2018 Jan 16;16(1):e2003714
  9. Wu SY, Chou HY, Yuh CH, Mekuria SL, Kao YC, Tsai HC, Radiation-Sensitive Dendrimer-Based Drug Delivery System. Advanced Science, 2017 Oct, 1700339  
  10. Tu HC, Hsiao YC, Yang WY, Tsai SL, Lin HK, Liao CY, Lu JW, Chou YT, Wang HD*, Yuh CH*, Up-Regulation of Golgi α-Mannosidase IA and Down-Regulation of Golgi α-Mannosidase IC Activates Unfolded Protein Response During Hepatocarcinogenesis, Hepatology Communications, 2017 Apr 19;1(3):230-247.

 

實驗室成員

 

Comments are closed.